Selected article for: "acute respiratory syndrome and lymph spleen node"

Author: Bai, Yan; Xu, Junling; Chen, Lijuan; Fu, Chang; Kang, Yi; Zhang, Weifeng; Fakhri, Georges EI; Gu, Jianqin; Shao, Fengmin; Wang, Meiyun
Title: Inflammatory response in lungs and extrapulmonary sites detected by [(18)F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus
  • Cord-id: kqwby4i7
  • Document date: 2021_1_9
  • ID: kqwby4i7
    Snippet: BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an ongoing global pandemic of coronavirus disease 2019 (COVID-19). The challenges associated with imaging infected patients have resulted, to date, in a paucity of metabolic imaging studies of patients with severe COVID-19 infection. Furthermore, it remains unclear if any abnormal metabolic events are taking place in patients who have recovered from COVID-19. PURPOSE: To use [(18)F] fluorodeoxyglucose ([
    Document: BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an ongoing global pandemic of coronavirus disease 2019 (COVID-19). The challenges associated with imaging infected patients have resulted, to date, in a paucity of metabolic imaging studies of patients with severe COVID-19 infection. Furthermore, it remains unclear if any abnormal metabolic events are taking place in patients who have recovered from COVID-19. PURPOSE: To use [(18)F] fluorodeoxyglucose ([(18)F] FDG) positron emission tomography/computed tomography (PET/CT) to measure metabolic activity in inflamed organs of patients convalescing post severe COVID-19 infection. MATERIALS AND METHODS: A prospective study was performed in seven convalescing patients who were recovering from severe COVID-19 infection in February 2020. Prior to [(18)F] FDG PET/CT, all patients had received two consecutive negative results of real-time reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 nucleic acid. Clinical intake including symptoms, treatment, laboratory test results, and follow-up was performed. The PET/CT images of COVID-19 patients were compared to a control group of patients that were matched for age and sex. RESULTS: Residual pulmonary lesions were present in all patients and maximum standard uptake value (SUVmax), average standard uptake value (SUVavg), maximum CT intensity (CTmax), and average CT intensity (CTavg) were all significantly greater than in the control group (p < 0.01 for all). In addition, SUVmax and SUVavg were significantly greater in the mediastinal lymph node and liver, and SUVmax was significantly greater in the spleen, of COVID-19 patients compared with controls (p < 0.05 for all). For the spleen, SUVmax (r(2) = 0.863, p = 0.003) and SUVavg (r(2) = 0.797, p = 0.007) were significantly correlated with blood lymphocyte count, and which was below the normal range in five of the seven (71.4%) patients convalescing post severe COVID-19 infection. CONCLUSION: [(18)F] FDG PET/CT quantitative analysis has shown that significant inflammation remained in lungs, mediastinal lymph nodes, spleen, and liver after two consecutive negative RT-PCR tests in patients convalescing post severe COVID-19 infection.

    Search related documents:
    Co phrase search for related documents
    • abnormal alanine aminotransferase and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • abnormal alanine aminotransferase and liver injury: 1, 2, 3, 4
    • abnormal alanine and acute respiratory syndrome: 1, 2, 3, 4
    • abnormal alanine and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal alanine and liver injury: 1, 2, 3
    • abnormal aspartate aminotransferase and acute respiratory syndrome: 1, 2, 3
    • abnormal aspartate aminotransferase and liver function: 1, 2, 3, 4, 5, 6
    • abnormal aspartate aminotransferase and liver injury: 1, 2, 3
    • abnormal aspartate and acute respiratory syndrome: 1, 2, 3
    • abnormal aspartate and liver function: 1, 2, 3, 4, 5, 6
    • abnormal aspartate and liver injury: 1, 2, 3
    • abnormal imaging and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abnormal imaging finding and acute respiratory syndrome: 1, 2
    • acid test result and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and additional energy: 1, 2
    • acute respiratory syndrome and adjacent region: 1, 2, 3, 4, 5
    • acute respiratory syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver spleen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25